Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: Does a J-shaped curve exist in smokers?

Journal of Hypertension

Volumn 21, Issue 4, 2003, Pages 797-804

  Zanchetti, Alberto ^a   Hansson, Lennart ^b   Clement, Denis ^c   Elmfeldt, Dag ^b,d   Julius, Stevo ^e   Rosenthal, Telma ^f   Waeber, Bernard ^g   Wedel, Hans ^h  

^a UNIVERSITY OF MILAN   (Italy)

^b UPPSALA UNIVERSITY   (Sweden)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d ASTRAZENECA R AND D   (Sweden)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f SHEBA MEDICAL CENTER   (Israel)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

Author keywords

Antihypertensive treatment; Diabetes mellitus; High global cardiovascular risk; Ischaemic heart disease; Smoking

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; SMOKING CESSATION;

EID: 0038708274     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200304000-00024     Document Type: Conference Paper

References (15)

1. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762.
2. Zanchetti A, Hansson L, Menard J, Leonetti G, Rahn KH, Warnold I, Wedel H, for the HOT Study Group. Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) Study. J Hypertens 2001; 19:819-825.
3. Zanchetti A, Hansson L, Dahlöf B, Elmfeldt D, Kjeldsen S, Kolloch R, et al. for the HOT Study Group. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment (HOT) Study. J Hypertens 2001; 19:1149-1159.
4. Kjeldsen SE, Kolloch RE, Leonetti G, Mallion JM, Zanchetti A, Elmfeldt D, et al. for the HOT Study Group. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. J Hypertens 2000; 18:629-642.
5. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1992; 1:113-119.
6. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17:151-183.
7. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002; 20:2099-2110.
8. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
9. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338:645-652.
10. Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, et al. for the Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340:677-684.
11. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000; 355:253-259.
12. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291:97-104.
13. The IPPPSH Collaborative Group. Cardiovascular risk and factors in a randomised trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 36:379-392.
14. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987; 1:581-584.
15. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 2001; 12:218-225.